Plasma membrane monoamine transporters: Structure, regulation and function

Nature Reviews Neuroscience

Volumn 4, Issue 1, 2003, Pages 13-25

  Torres, Gonzalo E ^a   Gainetdinov, Raul R ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMFEBUTAMONE; AMITRIPTYLINE; CARRIER PROTEIN; CITALOPRAM; COCAINE; DESIPRAMINE; DOPAMINE; IMIPRAMINE; MAZINDOL; MONOAMINE TRANSPORTER; NISOXETINE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; SEROTONIN; UNCLASSIFIED DRUG; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; BIOGENIC AMINE; MEMBRANE PROTEIN; NEUROPEPTIDE; VESICULAR AMINE TRANSPORTER;

AMINO ACID SEQUENCE; CELL MEMBRANE; DRUG DEPENDENCE; GILLES DE LA TOURETTE SYNDROME; HOMEOSTASIS; LESCH NYHAN SYNDROME; NEUROTRANSMITTER UPTAKE; OLIGOMERIZATION; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; WILSON DISEASE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; MOLECULAR GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BIOGENIC MONOAMINES; CELL MEMBRANE; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR SEQUENCE DATA; NEUROPEPTIDES; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS;

EID: 0037264650     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1008     Document Type: Article

References (175)

1. Hertting, G. & Axelrod, J. Fate of tritiated noradrenaline at the sympathetic nerve endings. Nature 192, 172-173 (1961).
2. Iversen, L. L. Role of transporter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol. 41, 571-591 (1971).
3. Amara, S. G. & Sonders, M. S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 51, 87-96 (1998).
4. Barker, E. L. & Blakely, R. D. in Psychopharmacology: The Fourth Generation of Progress (eds Bloom F. E. & Kupfer D. J.) 21-333 (Raven Press, Philadelphia, 1995).
5. Miller, G. W., Gainetdinov, R. R., Levey, A. I. & Caron, M. G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20, 424-429 (1999).
6. Giros, B. et al. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269, 15985-15988 (1994).
7. Carboni, E., Tanda, G. L., Frau, R. & Di Chiara, G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up In vivo by noradrenergic terminals. J. Neurochem. 55, 1067-1090 (1990).
8. Moron, J. A., Brockington, A., Wise, R. A., Rocha, B. A. & Hope, B. T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22, 389-395 (2002).
9. Ritz, M. C., Lamb, R. J., Goldberg, S. R. & Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 237, 1219-1223 (1987).
10. Seiden, L. S., Sabol, K. E. & Ricaurte, G. A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33, 639-677 (1993).
11. Sulzer, D. et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108 (1995).
12. Jones, S. R., Gainetdinov, R. R., Wightman, R. M. & Caron, M. G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18, 1979-1986 (1998).*************************
13. Kuhar, M. J. Molecular pharmacology of cocaine: a dopamine hypothesis and its implications. Ciba Found. Symp. 166, 81-89 (1992).
14. Wise, R. A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6, 243-251 (1996).
15. Rudnick, G. & Wall, S. C. The molecular mechanism of ‘ecstasy’ 3, 4-methylenedioxy-methamphetamine (MDMA): serotonin transporters are targets for MDMA-induced serotonin release. Proc. NatlAcad. Sci. USA 89, 1817-1821 (1992).
16. Javitch, J. A. & Snyder, S. H. Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP Eur. J. Pharmacol. 106, 455-456 (1984).
17. Gainetdinov, R. R., Fumagalli, F, Jones, S. R. & Caron, M. G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322-1325 (1997).
18. Pacholczyk, T., Blakely, R. D. & Amara, S. G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350, 350-354 (1991).
19. Guastella, J. et al. Cloning and expression of a rat brain GABA transporter. Science 249, 1303-1306 (1990).
20. Kilty, J. E., Lorang, D. & Amara, S. G. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254, 578-579 (1991).
21. Shimada, S. et al. Cloning and expression of a cocaine- sensitive dopamine transporter complementary DNA. Science 254, 576-578 (1991).
22. Usdin, T. B., Mezey, E., Chen, C., Brownstein, M. J. & Hoffman, B. J. Cloning of the cocaine-sensitive bovine dopamine transporter. Proc. Natl Acad. Sci. USA 88, 11168-11171 (1991).
23. Giros, B., el Mestikawy, S. Bertrand, L. & Caron, M. G. Cloning and functional characterization of a cocaine- sensitive dopamine transporter. FEBS Lett. 295, 149-154 (1991).
24. Blakely, R. D. et al. Cloning and expression of a functional serotonin transporter from rat brain. Nature 354, 66-70 (1991).
25. Hoffman, B. J., Mezey, E. & Brownstein, M. J. Cloning of a serotonin transporter affected by antidepressants. Science 254, 579-580 (1991).
26. Giros, B. et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42, 383-390 (1992).
27. Vandenbergh, D. J. et al. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res. Mol. Brain Res. 15, 161-166 (1992).
28. Ramamoorthy, S. et al. Antidepressant- and cocaine- sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl Acad. Sci. USA 90, 2542-2546 (1993).
29. Bruss, M., Kunz, J., Lingen, B. & Bonisch, H. Chromosomal mapping of the human gene for the tricyclic antidepressant- sensitive noradrenaline transporter. Hum. Genet. 91, 278-280 (1993).
30. Corey, J. L., Quick, M. W., Davidson, N., Lester, H. A. & Guastella, J. A cocaine-sensitive Drosophila serotonin transporter: cloning, expression, and electrophysiological characterization. Proc. Natl Acad. Sci. USA 91, 1188-1192 (1994).
31. Demchyshyn, L. L. et al. Cloning, expression, and localization of a chloride-facilitated, cocaine-sensitive serotonin transporter from Drosophila meianogaster. Proc. NatlAcad. Sci. USA 91, 5158-5162 (1994).
32. Lingen, B., Bruss, M. & Bonisch, H. Cloning and expression of the bovine sodium- and chloride-dependent noradrenaline transporter. FEBS Lett. 342, 235-238 (1994).
33. Porzgen, P, Bonisch, H. & Bruss, M. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem. Biophys. Res. Comm. 215, 1145-1150 (1995).
34. Chang, A. S. et al. Cloning and expression of the mouse serotonin transporter. Brain Res. Mol. Brain Res. 43, 185-192 (1996).
35. Bruss, M., Porzgen, P., Bryan-Lluka, L. J. & Bonisch, H. The rat norepinephrine transporter: molecular cloning from PC12 cells and functional expression. Brain Res. Mol. Brain Res. 52, 257-262 (1997).
36. Fritz, J. D., Jayanthi, L. D., Thoreson, M. A. & Blakely, R. D. Cloning and chromosomal mapping of the murine norepinephrine transporter. J. Neurochem. 70, 2241-2251 (1998).
37. Jayanthi, L. D. et al. The Caenorhabditis eiegans gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. Mol. Pharmacol. 54, 601-609 (1998).
38. Mortensen, O. V, Kristensen, A. S., Rudnick, G. & Wiborg, O. Molecular cloning, expression and characterization of a bovine serotonin transporter. Brain Res. Mol. Brain Res. 71, 120-126 (1999).
39. Porzgen, P, Park, S. K., Hirsh, J., Sonders, M. S. & Amara, S. G. The antidepressant-sensitive dopamine transporter in Drosophila meianogaster. a primordial carrier for catecholamines. Mol. Pharmacol. 59, 83-95 (2001).
40. Miller, G. M., Yatin, S. M., De La Garza, R., Goulet, M. & Madras, B. K. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Brain Res. Mol. Brain Res. 87, 124-143 (2002).
41. Sandhu, S. K., Ross, L. S. & Gill, S. S. A cocaine insensitive chimeric insect serotonin transporter reveals domains critical for cocaine interaction. Eur. J. Biochem. 269, 3934-3944 (2002).
42. Masson, J., Sagne, M., Hamon, M. & El Mestikawy, S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51, 439-464 (1999).
43. Vandenbergh, D. J., Persico, A. M. & Uhl, G. R. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14, 1104-1106 (1992).
44. Bannon, M. J., Michelhaugh, S. K., Wang, J. & Sacchetti, P The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur. Neuropsychopharmacol. 11, 449-455 (2001).
45. Kawarai, T., Kawakami, H., Yamamura, Y. & Nakamura, S. Structure and organization of the gene encoding human dopamine transporter. Gene 195, 11-18 (1997).
46. Gelernter J. et al. Assignment of the norepinephrine transporter protein (NET1) locus to chromosome 16. Genomics 18, 690-692 (1993).
47. Porzgen, P., Bonisch, H., Hammermann, R. & Bruss, M. The human noradrenaline transporter gene contains multiple polyadenylation sites and two alternatively spliced C-terminal exons. Biochim. Biophys. Acta 1398, 365-370 (1998).
48. Kitayama, S., Morita, K. & Dohi, T. Functional characterization of the splicing variants of human norepinephrine transporter. Neurosci. Lett. 312, 108-112 (2001).
49. Sacchetti, P., Brownschidle, L. A., Granneman, J. G. & Bannon, M. J. Characterization of the 5’-flanking region of the human dopamine transporter gene. Mol. Brain Res. 74, 167-174 (1999).
50. Meyer, J. et al. Cloning and functional characterization of the human norepinephrine transporter gene promoter. J. Neural. Transm. 105, 1341-1350 (1998).
51. Heils, A. et al. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J. Neural Transm. 102, 247-254 (1995).
52. Kim, C. H., Kim, H. S., Cubells, J. F. & Kim, K. S. A previously undescribed intron and extensive 5’ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J. Biol. Chem. 274, 6507-6518 (1999).
53. Bruss, M., Hammermann, R., Brimijoin, S. & Bonisch, H. Antipeptide antibodies confirm the topology of the human norepinephrine transporter. J. Biol. Chem. 270, 9197-9201 (1995).
54. Hersch, S. M., Yi, H., Heilman, C. J., Edwards, R. H. & Levey, A. I. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol. 388, 211-227 (1997).
55. Chen, J. G., Liu-Chen, S. & Rudnick, G. Determination of external loop topology in the serotonin transporter by site- directed chemical labeling. J. Biol. Chem. 273, 12675-12681 (1998).
56. Androutsellis-Theotokis, A. & Rudnick, G. Accessibility and conformational coupling in serotonin transporter predicted internal domains. J. Neurosci. 22, 8370-8378 (2002).
57. Buck, K. J. & Amara, S. G. Chimeric dopamine- norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4- phenylpyridinium. Proc. Natl Acad. Sci. USA 91, 12584-12588 (1994).
58. Buck, K. J. & Amara, S. G. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol. Pharmacol. 48, 1030-1037 (1995).
59. Lee, S. H., Kang, S., Son, H. & Lee, Y. S. The region of dopamine transporter encompassing the 3rd transmembrane domain is crucial for function. Biochem. Biophys. Res. Commun. 246, 347-352 (1998).
60. Ferrer, J. V. & Javitch, J. A. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc. Natl Acad. Sci. USA 95, 9238-9243 (1998).
61. Chen, N., Ferrer, J. V, Javitch, J. A. & Justice, J. B. Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter. J. Biol. Chem. 275, 1608-1614 (2000).
62. 2+ switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc. Natl Acad. Sci. USA 99, 1683-1638 (2002).
63. Norregaard, L., Frederiksen, D., Nielsen, E. O. & Gether, U. Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J. 17, 4266-4273 (1998).
64. Kitayama, S. et al. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl Acad. Sci. USA 89, 7782-7785 (1992).
65. Barker, E. L., Moore, K. R., Rakhshan, F. & Blakely, R. D. Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J. Neurosci. 19, 4705-4717 (1999).
66. Chen, N., Vaughan, R. A. & Reith, M. E. The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J. Neurochem. 77, 1116-1127 (2001).
67. Lin, Z., Wang, W., Kopajtic, T., Revay, R. S. & Uhl, G. R. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol. Pharmacol. 56, 434-447 (1999).
68. Lin, Z., Wang, W. & Uhl, G. R. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains. Mol. Pharmacol. 58, 1581-1592 (2000).
69. Mitsuhata, C. et al. Tyrosine-533 of rat dopamine transporter: involvement in interactions with 1-methyl- 4-phenylpyridinium and cocaine. Brain Res. Mol. Brain Res. 56, 84-88 (1998).
70. Barker, E. L., Kimmel, H. L. & Blakely, R. D. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol. Pharmacol. 46, 799-807 (1994).
71. Barker, E. L. et al. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J. Biol. Chem. 273, 19459-19466 (1998).
72. Smicun, Y., Campbell, S. D., Chen, M. A., Gu, H. & Rudnick, G. The role of external loop regions in serotonin transport. Loop scanning mutagenesis of the serotonin transporter external domain. J. Biol. Chem. 274, 36058-36064 (1999).
73. Mortensen, O. V., Kristensen, A. S. & Wiborg, O. Species- scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J. Neurochem. 79, 237-247 (2001).
74. Chen, J. G., Sachpatzidis, A. & Rudnick, G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding J. Biol. Chem. 272, 28321-28327 (1997).
75. Chen, J. G. & Rudnick, G. Permeation and gating residues in serotonin transporter. Proc. Natl Acad. Sci. USA 97, 1044-1049 (2000).
76. Androutsellis-Theotokis, A., Ghassemi, F. & Rudnick, G. A conformationally sensitive residue on the cytoplasmic surface of serotonin transporter. J. Biol. Chem. 276, 45933-45938 (2001).
77. Stephan, M. M., Chen, M. A., Penado, K. M. & Rudnick, G. An extracellular loop region of the serotonin transporter may be involved in the translocation mechanism. Biochemistry 36, 1322-1328 (1997).
78. +, and methanethiosulfonate reagents. J. Biol. Chem. 276, 4038-4045 (2001).
79. Sur, C., Betz, H. & Schloss, P. A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter. Proc. Natl Acad. Sci. USA 94, 7639-7644 (1997).
80. Rudnick, G. & Clark, J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim. Biophys. Acta. 1144, 249-263 (1993).
81. Gu, H., Wall, S. C. & Rudnick, G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 7124-7130 (1994).
82. Fischer, J. F. & Cho, A. K. Chemicalrelease of dopamine from striatal homogenates: evidence for anexchange diffusion model. J. Pharmacol. Exp. Ther. 208, 203-209 (1979).
83. Mager, S. et al. Conducting states of a mammalian serotonin transporter. Neuron 12, 845-859 (1994).
84. Galli, A., Blakely, R. D. & DeFelice, L. J. Norepinephrine transporters have channel modes of conduction. Proc. Natl Acad. Sci. USA 93, 8671-8676 (1996).
85. Sonders, M. S., Zhu, S. J., Zahniser, N. R., Kavanaugh, M. P & Amara, S. G. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17, 960-974 (1997).
86. Ingram, S. L., Prasad, B. M. & Amara, S. G. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nature Neurosci. 5, 971-978 (2002).
87. Milner, H. E., Beliveau, R. & Jarvis, S. M. The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. Biochim. Biophys. Acta. 1190, 185-187 (1994).
88. Jess, U., El Far, O., Kirsch, J. & Betz, H. The membrane- bound rat serotonin transporter, SERT1, is an oligomeric protein. FEBS Lett. 394, 44-46 (1996).
89. Chang, A. S., Starnes, D. M. & Chang, S. M. Possible existence of quaternary structure in the high-affinity serotonin transport complex. Biochem. Biophys. Res. Commun. 249, 416-421 (1998).
90. Kilic, F. & Rudnick, G. Oligomerization of serotonin transporter and its functional consequences. Proc. Natl Acad. Sci. USA 97, 3106-3111 (2000).
91. Schmid, J. A. et al. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J. Biol. Chem. 276, 3805-3810 (2001).
92. Hastrup, H., Karlin, A. & Javitch, J. A. Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc. Natl Acad. Sci. USA 98, 10055-10060 (2001).
93. Torres G. E. et al. Oligomerization and trafficking of the human dopamine transporter: mutational analysis identifies critical domains important for the functional expression of the transporter. J. Biol. Chem. 11 November 2002 (doi:10.1074’jbc.m201926200).
94. Vaughan, R. A., Huff, R. A., Uhl, G. R. & Kuhar, M. J. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J. Biol. Chem. 272, 15541-15546 (1997).
95. Zhang, L., Coffey, L. L. & Reith, M. E. Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem. Pharmacol. 53, 677-688 (1997)
96. Bonisch, H., Hammermann, R. & Bruss, M. Role of protein kinase C and second messengers in regulation of the norepinephrine transporter. Adv. Pharmacol. 42, 183-186 (1998)
97. Ramamoorthy, S., Giovanetti, E., Qian, Y. & Blakely R. D. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J. Biol. Chem. 273, 2458-2466 (1998).
98. Qian, Y. et al. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J. Neurosci. 17, 45-57 (1997).
99. Zhu, S. J., Kavanaugh, M. P, Sonders, M. S., Amara, S. G. & Zahniser, N. R. Activation of protein kinase C inhibits uptake, currents and binding associated with the human dopamine transporter expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 282, 1358-1365 (1997).
100. Apparsundaram, S., Schroeter, S., Giovanetti, E. & Blakely, R. D. Acute regulation of norepinephrine transport: II. PKC- modulated surface expression of human norepinephrine transporter proteins. J. Pharmacol. Exp. Ther. 287, 744-751 (1998)
101. Daniels, G. M. & Amara, S. G. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274, 35794-35801 (1999).
102. Melikian, H. E. & Buckley, K. M. Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19, 7699-7710 (1999).
103. Ramamoorthy, S. & Blakely, R. D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285, 763-736 (1999)
104. Saunders, C. et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl Acad. Sci. USA 97, 6850-6855 (2000).
105. Daws, L. C. et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Comm. 290, 1545-1550 (2002).
106. Little, K. Y, Elmer, L. W., Zhong, H., Scheys, J. O. & Zhang, L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 61, 436-445 (2002).
107. Chang, M. Y. et al. Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein. J. Neurochem. 77, 754-761 (2001).
108. Sakai, N. et al. Modulation of serotonin transporter activity by a protein kinase C activator and an inhibitor of type 1 and 2A serine’threonine phosphatases. J. Neurochem. 68, 2618-2624 (1997).
109. Foster, J. D., Pananusorn, B. & Vaughan, R. A. Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J. Biol. Chem. 277, 25178-25186 (2002).
110. Zahniser, N. R. & Doolen, S. Chronic and acute regulation of Na+’Ch-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol. Ther. 92, 21-55 (2001).
111. Zhu, M. Y. & Ordway, G. A. Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J. Neurochem. 68, 134-141 (1997).
112. Zhu, M. Y., Blakely, R. D., Apparsundaram, S. & Ordway, G. A. Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine. J. Neurochem. 70, 1547-1555 (1998).
113. Benmansour, S. et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J. Neurosci. 19, 10494-10501 (1999).
114. Benmansour, S., Owens, W. A., Cecchi, M., Morilak, D. A. & Frazer, A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J. Neurosci. 22, 6766-6772 (2002).
115. Lew, R., Vaughan, R., Simantov, R., Wilson, A. & Kuhar, M. J. Dopamine transporters in the nucleus accumbens and the striatum have different apparent molecular weights. Synapse 8, 152-153 (1991).
116. Patel, A., Uhl, G. R. & Kuhar, M. J. Species differences in dopamine transporters: postmortem changes and glycosylation differences. J. Neurochem. 61, 496-500 (1993).
117. Patel, A. P., Cerruti, C., Vaughan, R. A. & Kuhar, M. J. Developmentally regulated glycosylation of dopamine transporter. Brain Res. Dev. Brain Res. 83, 53-58 (1994).
118. --dependent serotonin transporter expressed using recombinant baculovirus in insect cells. J. Biol. Chem. 269, 26303-26310 (1994).
119. Nguyen, T. T. & Amara, S. G. N-linked oligosaccharides are required for cell surface expression of the norepinephrine transporter but do not influence substrate or inhibitor recognition. J. Neurochem. 67, 645-655 (1996).
120. Melikian, H. E., Ramamoorthy, S., Tate, C. G. & Blakely, R. D. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol. Pharmacol. 50, 266-276 (1996).
121. Bauman, A. L. et al. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J. Neurosci. 20, 7571-7578 (2000).
122. Jess, U., El Far, O., Kirsch, J. & Betz, H. Interaction of the C-terminal region of the rat serotonin transporter with MacMARCKS modulates 5-HT uptake regulation by protein kinase C. Biochem. Biophys. Res. Comm. 294, 272-279 (2002).
123. Lee, F. J., Liu, F., Pristupa, Z. B. & Niznik H. B. Direct binding and functional coupling of a-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926 (2001).
124. Gwinn-Hardy, K. Genetics of parkinsonism. Mov. Disord. 17, 645-656 (2002).
125. Lehmensiek, V, Tan, E. M., Schwarz, J. & Storch, A. Expression of mutant a-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Neuroreport 13, 1279-1283 (2002).
126. Torres, G. E. et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30, 121-134 (2001).
127. Carneiro, A. M. et al. The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. J. Neurosci. 22, 7045-7054 (2002).
128. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M. & Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-712 (1996).
129. Xu, F. et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nature Neurosci. 3, 465-471 (2000).
130. Bengel, D. et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymeth- amphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53, 649-655 (1998).
131. Jones, S. R. et al. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl Acad. Sci. USA 95, 4029-4034 (1998).
132. Gainetdinov, R. R., Sotnikova, T D. & Caron, M. G. Monoamine transporter pharmacology and mutant mice Trends Pharmacol. Sci. 23, 367-373 (2002).
133. Gainetdinov, R. R. & Caron, M. G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 43, 261-284 (2003).
134. Murphy, D. L. et al. Consequences of engineered and spontaneous genetic alterations of the 5-HT transporter in mice, men, and women. Behav. Pharmacol. 10, S65 (1999).
135. 1B receptors in knock-out mice lacking the 5-HT transporter. Eur. J. Neurosci. 12, 2299-2310 (2000).
136. Rocha, B. A. et al. Cocaine self-administration in dopamine transporter knockout mice. Nature Neurosci. 1, 132-133 (1998).
137. Sora, I. et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl Acad. Sci. USA 95, 7699-7704 (1998).
138. Sora, I. et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl Acad. Sci. USA 98, 5300-5305 (2001).
139. Carboni, E. et al. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21, 1-4 (2001).
140. Budygin, E. A., John, C. E., Mateo, Y. & Jones, S. R. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine-transporter knockout mice. J. Neurosci. 22, RC222 (2002).
141. Hall, F. S. et al. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience 115, 153-161 (2002).
142. Gainetdinov, R. R. et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283, 397-401 (1999).
143. Laakso, A. & Hietala, J. PET studies of brain monoamine transporters. Curr. Pharm. Des. 6, 1611-1623 (2000).
144. Volkow, N. D. et al. Decreased dopamine transporters with age in health human subjects. Ann. Neurol. 36, 237-239 (1994).
145. Kim, H. J. et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson’s disease subjects. J. Nucl. Med. 38, 1703-1711 (1997).
146. 23I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease. J. Neurol. Neurosurg. Psychiatry 65, 60-64 (1998).
147. Wong, D. F. et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc. Natl Acad. Sci. USA 93, 5539-5543 (1996).
148. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette’s disorder. Am. J. Psychiatry 152, 1359-1361 (1995).
149. Laasonen-Balk, T. et al. Striatal dopamine transporter density in major depression. Psychopharmacology 144, 282-285 (1999).
150. Dougherty, D. D. et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354, 2132-2133 (1999).
151. Tiihonen, J. et al. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour. Eur. J. Nucl. Med. 24, 1253-1260 (1997).
152. Heinz, A. et al. Reduced central serotonin transporters in alcoholism. Am. J. Psychiatry 155, 1544-1549 (1998).
153. 123I]-2 β-carbomethoxy-3 β -(4-iodophenyl)tropane and single photon emission computed tomography. Biol. Psychiatry 44, 1090-1098 (1998).
154. Klimek, V. et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci. 17, 8451-8458 (1997).
155. Cook, E. H. Jr et al. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56, 993-998 (1995).
156. Lesch, K. P. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531 (1996).
157. Bengel, D. et al. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive- compulsive disorder. Mol. Psychiatry 4, 463-466 (1999).
158. Seeger, G., Schloss, P. & Schmidt, M. H. Functional polymorphism within the promotor of the serotonin transporter gene is associated with severe hyperkinetic disorders. Mol. Psychiatry 6, 235-238 (2001).
159. Manor, I. et al. Family-based association study of the serotonin transporter promoter region polymorphism (5-HTTLPR) in attention deficit hyperactivity disorder. Am. J. Med. Genet. 105, 91-95 (2001).
160. Shannon, J. R. et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N. Engl. J. Med. 342, 541-549 (2000).
161. Hoffman, B. J., Hansson, S. R., Mezey, E. & Palkovits, M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front. Neuroendocrine. 19, 187-231 (1998).
162. Freed, C. et al. Dopamine transporter immunoreactivity in rat brain. J. Comp. Neurol. 359, 340-349 (1995).
163. Ciliax, B. J. et al. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15, 1714-1723 (1995).
164. Schroeter, S. et al. Immunolocalization of the cocaine- and antidepressant-sensitive L-norepinephrine transporter. J. Comp. Neurol. 420, 211 -232 (2000).
165. Qian, Y., Melikian, H. E., Rye, D. B., Levey, A. I. & Blakely, R. D. Identification and characterization of antidepressant- sensitive serotonin transporter proteins using site-specific antibodies. J. Neurosci. 15, 1261-1274 (1995).
166. Sur, C., Betz, H. & Schloss, P Immunocytochemical detection of the serotonin transporter in rat brain. Neuroscience 73, 217-231 (1996).
167. Nirenberg, M. J. et al. The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 17, 6899-6997 (1997).
168. Zhou, F. C., Tao-Cheng, J. H., Segu, L., Patel, T. & Wang, Y. Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res. 805, 241-254 (1998).
169. Pickel, V. M. & Chan, J. Ultrastructural localization of the serotonin transporter in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 19, 7356-7366 (1999).
170. Eisenhofer, G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol. Ther. 91, 35-62 (2001).
171. Talvenheimo, J. & Rudnick, G. Solubilization of the platelet plasma membrane serotonin transporter in an active form. J. Biol. Chem. 255, 8606-8611 (1980).
172. Wade, P. R. et al. Localization and function of a 5-HT transporter in crypt epithelia of the astrointestinal tract. J. Neurosci. 16, 2352-2364 (1996).
173. Schroeter, S., Levey, A. I. & Blakely, R. D. Polarized expression of the antidepressant-sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland. Mol. Cell. Neurosci. 9, 170-184 (1997).
174. Kimelberg, H. K. & Katz, D. M. High-affinity uptake of serotonin into immunocytochemically identified astrocytes. Science 228, 889-891 (1985).
175. Chen, N. & Reith, M. A. in Neurotransmitter Transporters 2nd edn (ed. Reith, M. E. A.) 60 (Humana Press, New Jersey, 2002).